Table I.
Agent | (Refs.) |
---|---|
First-line therapy (primary/neoadjuvant/adjuvant therapy or metastatic disease) | |
Cisplatin and doxorubicin | (36–38) |
MAP (high-dose methotrexate, cisplatin, and doxorubicin) | (39,40) |
Doxorubicin, cisplatin, ifosfamaide, and high-dose methotrexate | (41) |
Ifosfamide, cisplatin, and epirubicin | (42) |
Second-line therapy (relapsed/refractory or metastatic disease) | |
Docetaxel and gemcitabine | (30) |
Cyclophosphamide and etoposide | (43) |
Cyclophosphamide and topotecan | (18) |
Gemcitabine | (44) |
Ifosfamide (high dose)+/− etoposide | (26,28) |
Ifosfamide, carboplatin and etoposide | (29) |
High-dose methotrexate, etoposide and ifosfamide | (45) |
153Sm-EDTMP for relapsed or refractory disease beyond second-line therapy | (40) |
Ra223 | (41,46,47) |
Sorafenib | (48) |
Sorafenib+everolimus | (49) |
NCCN, National Comprehensive Cancer Network; 153Sm-EDTMP, samarium lexidronam.